Clinical Trials · NCT02592746
A Study of Palbociclib With Exemestane Plus GnRH Versus Capecitabine in Premenopausal Women With HR+ MBC
- Phase
- Phase 2
- Recruitment status
- Unknown
- Sponsor
- Samsung Medical Center
- Enrollment
- 182
- Start date
- Jun 2016
- Locations
- 2 sites, South Korea
- Primary endpoint
- Progression free survival (PFS) in patients with metastatic breast cancer who received palbociclib plus exemestane with goserelin versus capecitabine